Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Amyloid. 2020 Aug 19;28(1):30–34. doi: 10.1080/13506129.2020.1810010

Table 2.

Method of anticoagulation in patients with AF and ATTR-CA

Method of anticoagulation Number of patients (n=217)
Warfarin 78 (35.9%)
NOAC 116 (53.5%)
 Dabigatran 10 (4.6%)
 Rivoraxaban 45 (20.7%)
 Apixaban 60 (27.6%)
Warfarin switched to NOAC 4 (1.8%)
No anticoagulation 21 (9.7%)
 Patient declined 3 (1.4%)
 Adverse event with anticoagulation 3 (1.4%)
 End of life / hospice 2 (0.9%)
 Peri transplant 3 (1.4%)
 Unknown 10 (4.6%)